HIV as a Chronic DiseaseA Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults.
Althoff KN, McGinnis KA, Wyatt CM, et al. Clin Infect Dis. 2015;60(4):627-638.
Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: week 144 results.
Arribas JR, Thompson M, Sax PE, et al. J Acquir Immune Defic Syndr. 2017;75(2):211-218.
Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study.
Boyd MA, Mocroft A, Ryom L, et al. PLoS Med. 2017;14(11):e1002424.
Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals.
Brown TT, Chen Y, Currier JS, et al. J Acquir Immune Defic Syndr. 2013;63(3):323-330.
Management of HIV/AIDS in older patients-drug/drug interactions and adherence to antiretroviral therapy.
Burgess MJ, Zeuli JD, Kasten MJ. HIV AIDS. 2015;7:251-264.
Cohen SD, Kopp JB, Kimmel PL. N Engl J Med. 2017;377(24):2363-2374.
Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.
Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Clin Infect Dis. 2010;51(5):496-505.
Superior efficacy and improved renal and bone safety after switching from a tenofovir disoproxil fumarate- to a tenofovir alafenamide-based regimen through 96 weeks of treatment.
DeJesus E, Haas B, Segal-Maurer S, et al. AIDS Res Hum Retroviruses. 2018;34(4):337-342.
Erqou S, Lodebo BT, Masri A, et al. JACC Heart Fail. 2019;7(2):98-108.
Immediate initiation of antiretroviral therapy for HIV infection accelerates bone loss relative to deferring therapy: findings from the START bone mineral density substudy, a randomized trial.
Hoy JF, Grund B, Roediger M, et al. J Bone Miner Res. 2017;32(9):1945-1955.
INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. New Engl J Med. 2015;373(9):795-807.
Krawczyk CS, Holmberg SD, Moorman AC, Gardner LI, McGwin GJ, HIV Outpatient Study Group. AIDS. 2004;18(16):2171-2178.
Longenecker CT. Vasc Med. 2018;23(5):476-477.
Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients.
Ma Q, Vaida F, Wong J, et al. J Neurovirol. 2016;22(2):170-178.
McArthur JC, Steiner J, Sacktor N, Nath A. Ann Neurol. 2010;67(6):699-714.
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
Molina JM, Squires K, Sax PE, et al. Lancet HIV. 2018;5(5):e211-e220.
Moscicki AB, Darragh TM, Berry-Lawhorn JM, et al. J Low Genit Tract Dis. 2015;19(3 Suppl 1):S27-42.
Nasi M, De Biasi S, Gibellini L, et al. Clin Exp Immunol. 2017;187(1):44-52.
Park LS, Hernández-Ramírez RU, Silverberg MJ, Crothers K, Dubrow R. AIDS. 2016;30(2):273-291.
Premaor MO, Compston JE. JBMR Plus. 2018;2(5):247-256.
Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: a nationwide population-based cohort study.
Rasmussen LD, May MT, Kronborg G, et al. Lancet HIV. 2015;2(7):e288-298.
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.
Sax PE, Zolopa A, Brar I, et al. J Acquir Immune Defic Syndr. 2014;67(1):52-58.
Saylor D, Dickens AM, Sacktor N, et al. Nat Rev Neurol. 2016;12(4):234-248.
Torres HA, Rallapalli V, Saxena A, et al. Clin Microbiol Infect. 2014;20(10):O672-O679.
Vachiat A, McCutcheon K, Tsabedze N, Zachariah D, Manga P. J Am Coll Cardiol. 2017;69(1):73-82.
Wiggins BS, Lamprecht DG, Jr., Page RL, 2nd, Saseen JJ. Am J Cardiovasc Drugs. 2017;17(5):375-389.
Wing EJ. Int J Infect Dis. 2016;53:61-68.
HIV as a Chronic Disease: A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
The PCPs Role in Preventing HIV
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
What Do You Know About PrEP?
Got it? Treat it!
The Critical Role of the Community Pharmacist
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
Key Issues Impacting OB/GYN Practice
Hot Topics in HBV, HCV, and NASH
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Why It Matters in OB/GYN Practice Today
How the Pharmacist Can Make a Difference
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Understanding the Growing Syndemic — Opioids, HCV, and HIV
A PrEP Primer
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
The Rapid ART Standard of Care: From Evidence to Healthcare Equity
Maximizing Your Role to Impact Patient Outcomes
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Benefits, Barriers, & Best Practices in an Advancing Field
Practical Solutions Across the Spectrum of Care
A PEP/PrEP Training Guide for Pharmacists
A Critical Step Toward HCV Elimination
Considering the Patient, the Provider, and the Science
A Multidisciplinary Online Mini-Curriculum
Debates and Discussions about Monoclonal Antibody Therapies
An Update on Monoclonal Antibody Therapies
Establishing Clinical Readiness Through Mentored Learning
Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment
An Update on Best Practices
New Avenues to Pre-Exposure Prophylaxis
An Updated Clinician’s Guide to Assessment and Management
What the Pharmacist Needs to Know
A Look at the Changing HIV Playing Field
A “How To” Series Spanning Policy to Practice
Test Your Mastery!
Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention
Bringing HIV Prevention to a New Level
Optimizing HIV Prevention in Primary Care
Monoclonal Antibodies for the Prevention and Treatment of COVID-19
Current Prevention and Treatment Strategies